Parkinson’s treatment Archives

Comic-style illustration of Michael J. Fox pointing toward a glowing brain, alongside Parkinson’s research labs, medicines and rising stock-market arrows.

Parkinson’s Drug Stocks Enter a New Chapter as Michael J. Fox’s Mission Meets Medical Momentum -( $ABBV $IBB $SER $SUPN $XBI )

by John F. Heerdink, Jr. November 2, 2026 385Views 0Likes

Michael J. Fox’s promotion to Companion of the Order of Canada on October 2, 2026, recognized a remarkable transformation: a celebrated actor had become one of the world’s most consequential advocates for Parkinson’s research. His foundation, established in 2000, has funded approximately…

Conceptual Serina Therapeutics laboratory illustration with neurons, drug-delivery imagery and a display highlighting a potential 2027 clinical milestone.

Serina Therapeutics: A Parkinson’s Bet Where Delivery Is the Message -( $ABBV $SER )

by John F. Heerdink, Jr. October 26, 2026 250Views 0Likes

As SER-252 advances into its second dose cohort, Serina is building a case that improving how a medicine reaches patients can be as consequential as discovering the medicine itself. Serina Therapeutics, Inc. (NYSE American: SER) is pursuing an appealing proposition in biotechnology:…

Comic-style illustration of Michael J. Fox pointing toward Parkinson’s research and clinical trial displays, surrounded by scientists, patients and investors, with upward arrows symbolizing progress and investor optimism.

The Michael J. Fox Foundation Is Building Parkinson’s Next Chapter. Investors Have Reason to Pay Attention. -( $ABBV $IBB $SER $XBI )

by John F. Heerdink, Jr. October 8, 2026 509Views 0Likes

Better biomarkers, new FDA approvals and an emerging delivery pipeline strengthen the case for Parkinson’s innovation, with AbbVie and Serina Therapeutics offering distinct investment angles. The most compelling Parkinson’s investment story does not begin with a stock chart. It begins with a…

Investor-focused healthcare graphic showing a laboratory scene, a clinician holding a drug-delivery device, a glowing brain illustration, molecular imagery and a city skyline. The image highlights AbbVie Inc. (NYSE: ABBV) receiving FDA approval for JUVMO (tavapadon) for Parkinson’s disease and positions Serina Therapeutics Inc. (NYSE American: SER) and its SER-252 program as a potential next-generation therapy opportunity in advanced Parkinson’s disease.

AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI )

by John F. Heerdink, Jr. September 29, 2026 629Views 0Likes

AbbVie Inc. (NYSE: ABBV) has secured (Sept. 28) FDA approval for JUVMO™ (tavapadon), a new once-daily Parkinson’s therapy, adding an important fresh option to a market long defined by the delicate art of managing motor symptoms, “OFF” time, dyskinesia and medication burden. For Serina…

Comic-book-style Wall Street illustration featuring a charging bull superhero, symbols of insider conviction and high-speed OLED technology, virtual-care clinicians, and a scientist representing Parkinson’s disease research, beneath the headline “Wall Street’s Bullish New Menu.”

Wall Street’s Bullish New Menu: Insider Conviction, OLED Speed, Virtual Care and a Parkinson’s Catalyst -( $AMWL $GME $LPL $PFE $SER $XBI )

by John F. Heerdink, Jr. September 22, 2026 351Views 0Likes

The market’s most compelling bullish narratives rarely arrive wearing the same uniform. This week, they span a CEO buying millions of dollars of his own stock, an OLED display running at a downright impolite 720Hz, a telehealth company pursuing large institutional accounts,…

Illustration of an older man with Parkinson’s symptoms beside a laboratory researcher holding a syringe, with a large brain diagram showing dopamine pathways, sustained drug release, motor control, and Serina Therapeutics’ Parkinson’s disease drug-delivery innovation.

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

by John F. Heerdink, Jr. September 8, 2026 360Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) is building a potentially compelling clinical and platform-driven story around a familiar biotech proposition: take a medicine with demonstrated utility, improve the way it behaves in the body, and create a product patients may find meaningfully…

Tag: Parkinson’s treatment

Parkinson’s Drug Stocks Enter a New Chapter as Michael J. Fox’s Mission Meets Medical Momentum -( $ABBV $IBB $SER $SUPN $XBI )

Serina Therapeutics: A Parkinson’s Bet Where Delivery Is the Message -( $ABBV $SER )

The Michael J. Fox Foundation Is Building Parkinson’s Next Chapter. Investors Have Reason to Pay Attention. -( $ABBV $IBB $SER $XBI )

AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI )

Wall Street’s Bullish New Menu: Insider Conviction, OLED Speed, Virtual Care and a Parkinson’s Catalyst -( $AMWL $GME $LPL $PFE $SER $XBI )

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

Your Guide To Staying Informed In The Markets